Abstract
The aortal stenosis is the most frequent valve abnormality in adult. According to Euro Hear Survey one third of patients with significant AS were contraindicated for surgical aortic valve replacement (AVR) due to a high risk of surgery.
The percutaneous aortic valve replacement (TAVI) is the alternative treatment. Currently, the patients contraindicated for AVR due to a high risk of open heart surgery are indicated for TAVI.
Goal: To evaluate the clinical and echocardiographic follow-up parameters for patients after TAVI. Methods: 55 patients (including 30 women) underwent TAVI in our hospital since April 2009.
In 98.2 % this procedure was successful. The patients were checked including echocardiography one to six months after this treatment.
NYHA classification was applied as the clinical criterium. Results: Peri-procedural mortality was 1.8 %.
The mortality after 30 days and after six months was 4.1 % and 7.7 %, respectively. Fourteen and 25.6 % were hospitalized as a results of checkup one and six months after the TAVI, respectively.
After six months the majority of patients were classified with NYHA I or II. Before the treatment the average EF was 51.18 - 10.03, PG max. on the aortic valve was 68.49 - 19.7 mmHg, Vmax. 3.97m/s - 0.56.
After six months the EF was 54.1 - 9.2 %, Vmax 1.89 - 0.47 m/s, PG max. 14.35 - 7.04 mmHg. We did not register any significant aortic regurgitation (AR).
We observed non-significant AR (1/4) and mild AR (2/4) in 40 % and 16 % of patients, respectively. Conclusion: Our study performed on a small amount of patients confirm that TAVI is an efficient and save treatment for patients with significant symptomatic AS and a high risk of surgery.
Echocardiographic and clinical results are comparable with published data. In addition, this treatment is the only alternative for patients contraindicated for surgery valve replacement due to the high risk of surgery.